Comparison of actigraphic, polysomnographic, and subjective assessment of sleep parameters in sleep-disordered patients

Kushida, Clete A.; Chang, Arthur; Gadkary, Chirag; Guilleminault, Christian; Carrillo, Oscar; Dement, William C.

doi:10.1016/s1389-9457(00)00098-8

Cited by 856 publications

(665 citation statements)

References 9 publications

Supporting

Mentioning

631

Contrasting

Unclassified

Order By: Relevance

“…Previous studies, however, have shown that self-reported sleep duration is representative for habitual sleep duration. 39,40 The strengths of our study are data being collected yearly throughout puberty from a relatively large, general-population, birth cohort, with a high rate of participation, strong tracking of BMI 24,25 and in which no interventions took place. Study members' heights and weights were measured directly, to provide objective assessments of BMI at all ages.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sleep duration and body-weight development during puberty in a Dutch children cohort

et al. 2010

View full text Add to dashboard Cite

Background: Short sleep duration is associated with obesity during childhood and adulthood. Objective: The objective of our study was to investigate the relationship between sleep duration and body mass index (BMI) from Tanner stages 1 to 5 in a Dutch children cohort. Design: In 98 children, anthropometric measurements and leptin concentrations were measured from age 7 to 16 years; body composition, physical activity (Baecke questionnaire), hours television viewing and self-reported sleep duration were measured yearly from age 12 to 16 years. Moreover, the polymorphisms of the FTO gene (rs9939609) and parental BMI's were determined. Results: At Tanner stages 1-5 sex differences were observed in height, body weight, waist circumference, fat mass per squared meter height and leptin concentrations per kg fat mass. Inverse relationships were observed between the change in BMI (kg m -2 ) and the change in hours of sleep per night (h) from Tanner stages 1 to 4 (r ¼ À0.68, Po0.001), from Tanner stages 2 to 5 (r ¼ À0.35, Po0.05) and from Tanner stages 1 to 5 (r ¼ À0.33, Po0.05). Univariate analysis of variance showed that with progressive Tanner stages, BMI increases and sleep duration decreases in an interrelated way independent of possible confounders (R 2 ¼ 0.38, Po0.02). Conclusion: Changes in BMI during puberty were inversely related to changes in sleep duration, independent of possible confounders.

show abstract

Section: Discussionmentioning

confidence: 99%

“…', which the children themselves answered and which is supposed to represent their habitual sleep duration. 39,40 Sleep duration was measured at age 12, 13, 14, 15 and 16 years.…”

Section: Sleep Durationmentioning

confidence: 99%

Sleep duration and body-weight development during puberty in a Dutch children cohort

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Although sleep was not assessed by polysomnography, actigraphy allows objective estimation of changes in sleep variables without affecting sleep. 40 We used 2.5-mg oral melatonin to ensure plasma melatonin levels at or above endogenous nighttime levels for 4 to 8 hours after intake, thus during most of the sleeping period. 41 Melatonin (1 to 5 mg) has been widely used as a nutritional supplement in the United States for several years, without any serious adverse side effects being reported.…”

Section: Discussionmentioning

confidence: 99%

Daily Nighttime Melatonin Reduces Blood Pressure in Male Patients With Essential Hypertension

et al. 2004

View full text Add to dashboard Cite

Abstract-Patients with essential hypertension have disturbed autonomic cardiovascular regulation and circadian pacemaker function. Recently, the biological clock was shown to be involved in autonomic cardiovascular regulation. Our objective was to determine whether enhancement of the functioning of the biological clock by repeated nighttime melatonin intake might reduce ambulatory blood pressure in patients with essential hypertension. We conducted a randomized, double-blind, placebo-controlled, crossover trial in 16 men with untreated essential hypertension to investigate the influence of acute (single) and repeated (daily for 3 weeks) oral melatonin (2.5 mg) intake 1 hour before sleep on 24-hour ambulatory blood pressure and actigraphic estimates of sleep quality. Repeated melatonin intake reduced systolic and diastolic blood pressure during sleep by 6 and 4 mm Hg, respectively. The treatment did not affect heart rate. The day-night amplitudes of the rhythms in systolic and diastolic blood pressures were increased by 15% and 25%, respectively. A single dose of melatonin had no effect on blood pressure. Repeated (but not acute) melatonin also improved sleep. Improvements in blood pressure and sleep were statistically unrelated. In patients with essential hypertension, repeated bedtime melatonin intake significantly reduced nocturnal blood pressure. Future studies in larger patient group should be performed to define the characteristics of the patients who would benefit most from melatonin intake. The present study suggests that support of circadian pacemaker function may provide a new strategy in the treatment of essential hypertension. Key Words: blood pressure monitoring Ⅲ circadian rhythm Ⅲ hormones Ⅲ human Ⅲ hypertension T he endogenous circadian pacemaker, located in the suprachiasmatic nucleus (SCN), imposes 24-hour biological rhythms by endocrine and autonomic mechanisms. 1 For example, the circadian rhythm in adrenal cortex activity is regulated via an endocrine and a sympathetic route, 2,3 that of heart and liver via sympathetic and parasympathetic control, 4 -6 and of the pineal gland via the sympathetic nervous system. 7 Thus, the SCN promotes adaptation to the rest and activity periods by regulating, for example, the morning increase in cortisol, heart rate, and glucose, and the evening increase in melatonin.Evidence for disturbed circadian pacemaker function in essential hypertension is accumulating. Patients with hypertension show blunted day-night rhythms in sympathetic and parasympathetic heart tone. 8,9 Patients with coronary heart disease, a major complication of chronic hypertension, show a blunted day-night rhythm in vasodilatation 10 and suppressed nighttime melatonin levels. 11 We demonstrated recently that in comparison with normotensive subjects, the levels of three important SCNneurotransmitters are reduced by more than 50% in patients with essential hypertension, 12 corroborating its functional impairment. Furthermore, we provided anatomical support for a changed SCN output to the symp...

show abstract

“…Objective measures of sleep were obtained by tracking gross motor activity using Actiwatch® Activity Monitoring System (Actiwatch: Respironics Company, Bend, OR), worn throughout the study by six of the 11 participants (Kushida et al 2001). Actiwatch® data from the first five participants were not available due to equipment malfunctions with another portable sleep system.…”

Section: Sleep Monitoringmentioning

confidence: 99%

Residual effects of intranasal methamphetamine on sleep, mood, and performance

Perez

Kirkpatrick

Gunderson

et al. 2008

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Although intranasal methamphetamine abuse has increased, there are no published data investigating the residual effects of the drug under controlled conditions. Thus, the current study examined the residual effects of single-dose intranasal methamphetamine administration on a broad range of behavioral and physiological measures. Non-treatment seeking methamphetamine abusers (n = 11) completed this two-week, in-patient, within-participant, double-blind study. The study consisted of 4 two-day blocks of sessions; each block was separated by at least 24 hrs. At approximately 1000 hrs, on the first day of each block, participants received one of four intranasal methamphetamine doses (0, 12, 25, 50 mg/70 kg). Lights were turned out at 2300 hrs that evening and sleep measures were assessed. On the morning of the second day of each block, methamphetamine plasma levels, cardiovascular measures, mood, subjective reports of the previous evening's sleep, and psychomotor performance were assessed to determine residual drug effects. The larger methamphetamine doses (25 and 50 mg) markedly disrupted subjective measures of that night's sleep and some indices of next-day mood, but only the largest dose (50 mg) dose decreased objective measures of that night's sleep and increased next-day physiological measures. Methamphetamine did not produce any negative residual effects on early next-day performance. Future studies should assess methamphetamine-related residual effects following repeated doses administered over consecutive days.

show abstract

Comparison of actigraphic, polysomnographic, and subjective assessment of sleep parameters in sleep-disordered patients

Cited by 856 publications

References 9 publications

Sleep duration and body-weight development during puberty in a Dutch children cohort

Sleep duration and body-weight development during puberty in a Dutch children cohort

Daily Nighttime Melatonin Reduces Blood Pressure in Male Patients With Essential Hypertension

Residual effects of intranasal methamphetamine on sleep, mood, and performance

Contact Info

Product

Resources

About